Meeting
2020 Gastrointestinal Cancers Symposium
mFOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer: The FOCULM study.
Authors
Huabin Hu
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Huabin Hu , Kun Wang , Wei Wang , Meng Qiu , Rongbo Lin , Haibo Zhang , GuangJian Liu , Yunle Wan , Liang Kang , Hui Wang , Zhiyang Zhou , Fangqian Li , Yan Huang , Jianwei Zhang , Yue Cai , Zehua Wu , Jiayu Ling , Meijin Huang , Yanhong Deng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02063529
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 99)
Abstract #
99
Poster Bd #
E7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO.
First Author: Veronica Conca
Poster
2023 ASCO Annual Meeting
The FOxTROT platform: Clinical trials and exploratory research for personalization of neoadjuvant (NA) therapy in locally advanced colon cancer (LACC)—ISRCTN83842641.
First Author: Christopher Williams
Poster
2021 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.
First Author: Wen Zhang
First Author: Valerie Boige